BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Citrome L. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int J Clin Pract 2015;69:151-5. [DOI: 10.1111/ijcp.12620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Citrome L. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract 2015;69:1211-20. [DOI: 10.1111/ijcp.12752] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 8.5] [Reference Citation Analysis]
2 Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G, Porter R, Singh AB. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087-206. [DOI: 10.1177/0004867415617657] [Cited by in Crossref: 414] [Cited by in F6Publishing: 325] [Article Influence: 69.0] [Reference Citation Analysis]
3 Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2016;196:225-33. [DOI: 10.1016/j.jad.2016.02.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 6.2] [Reference Citation Analysis]
4 Kahl KG, Westhoff-bleck M, Krüger TH. Effects of psychopharmacological treatment with antidepressants on the vascular system. Vascular Pharmacology 2017;96-98:11-8. [DOI: 10.1016/j.vph.2017.07.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
5 Atsou K, Ereshefsky L, Brignone M, Danchenko N, Diamand F, Mucha L, Touya M, Becker R, François C. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant. Expert Rev Pharmacoecon Outcomes Res 2021;21:29-42. [PMID: 33307885 DOI: 10.1080/14737167.2021.1855979] [Reference Citation Analysis]
6 Andersen RL, Johnson DJ, Patel JN. Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways. Pharmacogenomics 2016;17:417-34. [PMID: 26871520 DOI: 10.2217/pgs.15.178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]